COLUMBUS, Ohio, May 5 Roxane Laboratories, Inc. announcedtoday the approval of its Abbreviated New Drug Application (ANDA) forRopinirole Hydrochloride Tablets, 0.25mg ...
Philadelphia, PA (August 1, 2004) – New data published in the August issue of SLEEP shows that patients with primary Restless Legs Syndrome (RLS) and with periodic leg movements during sleep (PLMS), ...
Dr. Reddy’s Laboratories announced that it has launched Ropinirole Hydrochloride XR extended-release tablets - 2 mg, 4 mg, 6 mg, 8mg, and 12 mg - a bioequivalent generic version of REQUIP XL tablets ...
May 12, 2005 — The U.S. Food and Drug Administration (FDA) has approved ropinirole HCl tablets for the treatment of moderate to severe primary restless legs syndrome (RLS) in adults, budesonide ...
Glenmark Generics Inc., USA (GGI), a subsidiary of Glenmark Generics Limited (GGL), has received ANDA approval from the United States Food and Drug Administration (US FDA) for ropinirole hydrochloride ...
An early clinical trial headed by researchers at Keio University School of Medicine has shown that the Parkinson’s disease drug ropinirole is safe to use in patients with the fatal motor neuron ...
This Feb. 2, 2019 file photo shows professor Hideyuki Okano, left, giving a presentation on the progress of his research before ALS patients and others. (Mainichi/Suzuko Araki) TOKYO -- A Parkinson's ...
April 30, 2007 — Health Canada has approved an expanded indication for atorvastatin calcium tablets, allowing their use to reduce the risk for myocardial infarction in adult patients without ...
Results from a small clinical trial show that the Parkinson’s disease drug ropinirole delayed the progression of amyotrophic lateral sclerosis (ALS) by an average of 27.9 weeks. The study is published ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results